STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.

Slides:



Advertisements
Similar presentations
Prevalence, Predictors, and Long-Term Prognosis of Premature Discontinuation of Oral Antiplatelet Therapy After Drug Eluting Stent Implantation Roberta.
Advertisements

When PCI in NSTEMI? Giuseppe Biondi Zoccai, MD Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome.
Late Drug-Eluting Stent Thrombosis: Should we be worried?
Prasugrel vs ticagrelor in acute coronary syndromes
Can we prevent stent restenosis after coronary stent implantation
Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma
Pros and cons of FFR in multivessel disease: from FAME to ACS Giuseppe Biondi Zoccai University of Modena and Reggio Emilia, Modena, Italy
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
New-generation drug-eluting stents and dual antiplatelet therapy: overview Giuseppe Biondi Zoccai, MD Department of Medico-Surgical Sciences and Biotechnologies.
CURRENT PUBLICATION TRENDS IN INTERVENTIONAL CARDIOLOGY Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Biondi-Zoccai: Peripheral interventions – metcardio.org Basic principles of peripheral interventions Giuseppe Biondi Zoccai University.
Giuseppe Biondi-Zoccai, MD Sapienza University of Rome, Latina, Italy Stent thrombosis: the meta-analytic.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
ACUTE CORONARY SYNDROMES:
CYPHER® Clinical Evidence in Acute Myocardial Infarction (AMI)
A Systematic Review On The Hazards Of Aspirin Discontinuation Among Patients With Or At Risk For Coronary Artery Disease Giuseppe Biondi Zoccai Hemodynamics.
Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.
Applications of bivalirudin in interventional cardiology
1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Giuseppe Biondi Zoccai Division of Cardiology University of Turin, Turin Critical aspects of trials on the new generation DES 31st.
Unresolved issues with Drug-eluting Stents Stent Thrombosis Advanced Angioplasty 2007 Dan Blackman Yorkshire Heart Centre.
Is personalized medicine a hoax? Giuseppe Biondi Zoccai, MD University of Modena and Reggio Emilia
The Pathology of Cardiac Interventions Dr Stephen Preston Royal Bournemouth Hospital Dr Patrick J Gallagher University of Southampton.
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.
Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
Multivessel PCI on top of culprit lesion revascularization? No way!
COMPLETE REVASCULARIZATION IN ELDERLY - When it’s contraindicated
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy JOINT SYMPOSIUM WITH JACCT - Bologna, 25/9/2008.
Why are drug-eluting stents safer than bare-metal stents? Giuseppe Biondi Zoccai, MD Sapienza University of Rome, Rome, Italy METCARDIO,
PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Drug-eluting stent meta-analyses & Long-term follow-up of high-risk subsets: Reconciling the evidence DES e BMS: riflessioni e pensieri 23 febbraio 2007,
1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.
M. Valgimigli, MD, PhD University of Ferrara, ITALY On behalf of the PRODIGY Investigators PROlonging Dual antiplatelet treatment after Grading stent-induced.
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy BMS & Sanofi Aventis Sponsored.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
In-Stent Restenosis and Late Stent Thrombosis
Drug-Eluting Stents in Challenging Lesions: Randomized Trials and Registries.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,
On behalf of J. Belardi, M. Leon, L. Mauri,
Second Generation DES Associated with Less Late and Very Late Stent Thrombosis Compared to First Generation DES Donald E. Cutlip, MD Beth Israel Deaconess.
Giuseppe Biondi Zoccai
Bern-Rotterdam Registry Published in the Lancet
Giuseppe Biondi Zoccai
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
Background There is ongoing debate to identify the most effective drug-eluting stent between the two currently most used devices (ie, sirolimus- [SES]
Giuseppe Biondi Zoccai University of Turin, Turin, Italy
Giuseppe Biondi Zoccai, MD
Impact of Platelet Reactivity Following Clopidogrel Administration
SURGERY EARLY AFTER DES IMPLANTATION
Benefits of complete coronary revascularization – Counterpoint: what are you talking about? Giuseppe Biondi Zoccai, MD University of Modena and Reggio.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Late Thrombosis in Drug Eluting Stents (DES)
Single Versus Multiple Vessel Stenting In Patients With St-Elevation Myocardial Infarction: Results From A 30,886-Patient Meta-Analysis Giuseppe Biondi.
ORAL CILOSTAZOL TREATMENT PREVENTS RESTENOSIS AND MAJOR ADVERSE CLINICAL EVENTS AFTER DRUG-ELUTING STENT IMPLANTATION: EVIDENCE FROM A META-ANALYSIS G.
Comparison of radial versus femoral access in patients undergoing invasive management for acute coronary syndromes: evidence from a systematic review and.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.
Presentation transcript:

STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista “Molinette” Torino

2 Learning goals What is stent thrombosis? Can I predict stent thrombosis? What is the real impact of stent thrombosis?

3 Learning goals What is stent thrombosis? Can I predict stent thrombosis? What is the real impact of stent thrombosis?

4 Failing stents: thrombosis vs restenosis Schuchman, New Engl J Med 2006

5 Stent thrombosis in the medical literature Google Scholar searched for “stent AND thrombosis” on 8 June 2010

6 History of stent thrombosis IMPACT OF DUAL ANTIPLATELET THERAPY AND HIGH PRESSURE DILATION

7 Definition of stent thrombosis Acute occlusion of a previously patent stent It is a clinical syndrome (presents with acute coronary syndrome or sudden death – if silent cannot be defined stent thrombosis) It is not due to new plaque rupture at distant site There was no severe restenosis with final occlusion

8 Academic Research Consortium definitions Definite: Clinical syndrome (ACS or AMI) and angiographic evidence of thrombus or occlusion or pathologic evidence of acute thrombosis Probable: Unexplained death < 30 days or target vessel AMI without angiographic confirmation of thrombosis or other identified culprit lesion Possible: Unexplained death after 30 days Cutlip et al, Circulation 2007

9 Timing of stent thrombosis TypeOccurrence*Incidence Acute≤1 day+ Subacute2-30 days+++ Late2-12 months++ Very late>1 year++ *after PCI

10 Learning goals What is stent thrombosis? Can I predict stent thrombosis? What is the real impact of stent thrombosis?

11 Mechanisms of thrombosis: Virchow's triad BLOODFLOW VESSEL

12 Mechanisms of stent thrombosis PATIENT FACTORS LESION FACTORS PROCEDURAL & MEDICAL RX FACTORS

13 Genetic variability in risk of stent thrombosis Mega et al, New Engl J Med 2009

14 Predicting thrombosis according to diabetes Machecourt et al, J Am Coll Cardiol 2009

15 Predicting thrombosis according to stent length Moreno et al, J Am Coll Cardiol 2005

16 What about late stent thrombosis? McFadden et al, Lancet 2004 €

17 Impact of antiplatelet therapy discontinuation Kimura et al, Circulation 2009

18 Impact of antiplatelet therapy intensity Mehta et al, ESC 2009 Clopidogrel mg Clopidogrel mg P Definite stent thrombosis0.7%1.2%0.002 Myocardial infarction2.0%2.6%0.012 Stroke0.4% 0.59 Cardiovascular death1.9% 0.68 Myocardial infarction or stent thrombosis 3.0%3.7%0.008 Cardiovascular death, myocardial infarction, or stroke 3.9%4.5% day results of the CURRENT-OASIS 7 Trial

19 Predictors of drug-eluting stent thrombosis Iakovou et al, JAMA 2005

20 Predictors of stent thrombosis after ACS Van Werkum et al, J Am Coll Cardiol 2009

21 Any synthesis possible? Capodanno et al, Clin Res Cardiol 2009

22 Any synthesis possible? Capodanno et al, Clin Res Cardiol 2009

23 Learning goals What is stent thrombosis? Can I predict stent thrombosis? What is the real impact of stent thrombosis?

24 Timing and incidence of stent thrombosis Stents Early stent thrombosis Late stent thrombosis Very late stent thrombosis SES vs BMS 1 0.5% vs 0.3%0.1% vs 1.0%0.9% vs 0.4% PES vs BMS 1 0.5% vs 0.5%0.4% vs 0.3%0.9% vs 0.6% ZES vs BMS 2 0.3% vs 1.2%0.3% vs 0.1%0.1% vs 0.1% EES vs PES 3 0.4% vs 00.3% vs 0.6%0.3% vs 1.0% 1 Mauri et al, New Engl J Med Leon, TCT Stone et al, Circulation 2009

25 Incidence of stent thrombosis in Bern & Rotterdam Daemen et al, Lancet 2007

26 Incidence of stent thrombosis in Sweden Lagerqvist et al, Circulation Int 2009

27 Outlook after stent thrombosis Van Werkum et al, Circulation 2009

28 Impact of BMS thrombosis Cutlip et al, Circulation 2001

29 Impact of definite DES thrombosis Kuchulakanti et al, Circulation 2006

30 Impact of definite or probable DES thrombosis Mauri et al, New Engl J Med 2007

31 More on impact of DES thrombosis Daemen et al, Lancet 2007

32 Stent thrombosis in further perspective Daemen et al, Lancet 2007

33 Take home messages

34 Take home messages Stent thrombosis is a clinically important event, causing often death or myocardial infarction in those experiencing it Stent thrombosis is however rare, but it can be predicted by patient and lesion factors, and modulated by procedural, pharmacologic and other treatment decisions Thus, when addressing the issue of stent thrombosis, it is crucial to individualize management strategies in order to maximize benefits and minimize risks

35 Thank you for your attention For any correspondence: For these and further slides on these topics feel free to visit the metcardio.org website: